论文信息 - Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes. - 字舞流文

Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.

Ying Zhang | Wang Shen | Yumei Xiong | Qingxiang Liu | Ryo Okuyama | J. Reagan | W. Shen | M. Lizarzaburu | J. Medina | Sujen Lai | Xiaohui Du | Julio C Medina | Mike Lizarzaburu | Simon Turcotte | Peter Fan | Jonathan Houze | Leping Li | Leping Li | Sujen Lai | Xi Chen | A. Motani | Angela Fu | Michiko Murakoshi | Kozo Oda | Futoshi Nara | Zice Fu | F. Nara | Xiaohui Du | Z. Fu | Yong-Jae Kim | Xi Chen | Alykhan Motani | Jeff D Reagan | Jonathan B. Houze | Yumei Xiong | R. Okuyama | Yong-Jae Kim | Qingxiang Liu | S. Turcotte | K. Oda | Michiko Murakoshi | Angela Fu | Peter Fan | Ying Zhang

[1] Xiaohui Du and. Phenylalanine Derivatives as GPR142 Agonists for the Treatment of Type II Diabetes. , 2013 .

[2] S. Bharate,et al. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes , 2009, Expert opinion on therapeutic patents.

[3] Sayeeda Rahman,et al. Diabetes‐associated macrovasculopathy: pathophysiology and pathogenesis , 2007, Diabetes, obesity & metabolism.

[4] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[5] A. Vinik,et al. Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. , 2006, Current diabetes reviews.

[6] B. Nazimek-Siewniak,et al. Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. , 2002, Journal of diabetes and its complications.

[7] M. Burge,et al. Sulphonylurea‐induced hypoglycaemia in type 2 diabetes mellitus: a review , 1999, Diabetes, obesity & metabolism.